7→8: Insurance/NII thesis with all conv-8 criteria met. DCF P(above current) 100%, DCF FV $337 vs $139 = 142% upside. Analyst consensus 23.5% upside. Above 200dma. Rate environment favorable for investment income. Higher-for-longer rates = structural tailwind. Clear thesis + strong quantitative support across both DCF and consensus. Litigation overhang is known and sized.
Fair Value Distribution — percentile bands
100.0% of simulations place fair value above current price
WHAT IS PRICED IN
Revenue-Based Reverse DCF
-7.3%/yr
±2.7% · revenue growth to justify current price
KEY VALUE DRIVERS
Spearman correlation — what moves this valuation most
Conv 8. Insurance/NII with DCF P(above)=100%, DCF FV=$337 vs $139 = extraordinary undervaluation signal. Above 200dma. Higher-for-longer rates = structural NII tailwind. Litigation overhang is known and sized.
RSI 41 trending down, MACD negative, 5-day momentum -2.2%. Litigation overhang is real and creates sentiment drag. Caution regime — no momentum setup.
Litigation losses materially exceed reserve estimates, rate environment reversal, reserve deficiencies in life insurance
Updated Mar 18
Globe Life reported strong Q4 2025 results (March 23); Vanguard disclosed 12.67% stake. Texas Capital upgraded to Strong-Buy. Multiple positive catalysts this week — thesis intact and strengthening.
FY2025 10-K: Net income .16B (+8%), EPS .07 (+18%). Life margins expanding (45% reported, 41% normalized vs 40%). Medicare Supp surge (+36% health net sales). Excess investment income declining -16%. ...
FY2025 results exceed expectations: premium +5% to $4.89B, net income +8% to $1.16B ($14.07 EPS), life margins expanded to 45% (from 41%). Operating ROE 16%. Strong capital position with 316% RBC rati...
Strong operating performance with 5% premium growth, 18% EPS growth to $14.07. Life margins expanded to 45% on favorable mortality/assumption updates. Health benefiting from Medicare Advantage-to-Supp...
GL fundamentals solid: premium growth 5%, net income +8%, life margins expanding to 45% driven by better mortality and assumption gains. Strong agent momentum, defensive market positioning. Key watch:...